Coeptis Therapeutics (NASDAQ:ZSQR) vs. SoundHound AI (NASDAQ:SOUN) Critical Review

SoundHound AI (NASDAQ:SOUN) and Coeptis Therapeutics (NASDAQ:ZSQR) are both technology companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, dividends and analyst recommendations.

Profitability

This table compares SoundHound AI and Coeptis Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SoundHound AI	-67.45%	-30.22%	-20.28%
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%

Valuation and Earnings

This table compares SoundHound AI and Coeptis Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SoundHound AI	$168.92 million	16.09	-$14.01 million	($0.38)	-16.11
Coeptis Therapeutics	$1.36 million	108.73	-$11.92 million	($1.63)	-1.71

Coeptis Therapeutics has lower revenue, but higher earnings than SoundHound AI. SoundHound AI is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

19.3% of SoundHound AI shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 8.8% of SoundHound AI shares are owned by company insiders. Comparatively, 24.2% of Coeptis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

SoundHound AI has a beta of 2.66, indicating that its share price is 166% more volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for SoundHound AI and Coeptis Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SoundHound AI	1	2	3	1	2.57
Coeptis Therapeutics	1	0	0	0	1.00

SoundHound AI presently has a consensus price target of $12.75, indicating a potential upside of 108.33%. Given SoundHound AI’s stronger consensus rating and higher possible upside, research analysts plainly believe SoundHound AI is more favorable than Coeptis Therapeutics.

Summary

SoundHound AI beats Coeptis Therapeutics on 11 of the 15 factors compared between the two stocks.

About SoundHound AI

SoundHound AI, Inc. develops independent voice artificial intelligence (AI) solutions that enables businesses across automotive, TV, and IoT, and to customer service industries to deliver high-quality conversational experiences to their customers. Its products include Houndify platform that offers a suite of Houndify tools to help brands build conversational voice assistants, such as Application Programming Interfaces (API) for text and voice queries, support for custom commands, extensive library of content domains, inclusive software development kit platforms, collaboration capabilities, diagnostic tools, and built-in analytics; SoundHound Chat AI that integrates with knowledge domains, pulling real-time data like weather, sports, stocks, flight status, and restaurants; and SoundHound Smart Answering is built to offer customer establishments custom AI-powered voice assistant. The company's products also include CaiNET software that uses machine learning to enhance how domains work together to handle queries; CaiLAN software that arbitrates responses so users get answers from the right domain; Dynamic Interaction a real-time, multimodal customer service interface; Smart Ordering which offers an easy-to-understand voice assistant for restaurants; Employee Assist; automatic speech recognition; natural language understanding; wake words; custom domains; text-to-speech; and embedded voice solutions. The company was founded in 2005 and is headquartered in Santa Clara, California.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.